-
-
One of the most confusing areas in medicine, which spills over into obstetrics, is thrombophilia, and seemingly every year a new antibody affecting the clotting system emerges that causes worry. One of the worries involves a possible link with pre-eclampsia.
-
Arzoxifene is being developed by Eli Lilly and Co. to prevent bone loss and treat osteoporosis.
-
A review of any publication from 1960 to 2007 with the main outcome of time to fertility following oral contraceptive discontinuation was performed.
-
During the last two months an unusual number of papers were published which, while not having earth-shaking scientific value, should have some clinical impact.
-
Data from the Surveillance Epidemiology and End Results (SEER) registry have consistently demonstrated improved life expectancy for women with epithelial ovarian cancer every year since 1973.
-
n this issue: NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.
-
-
In a retrospective analysis of 3681 women who underwent endometrial ablation from 1999 to 2004, data analyzed in 2007 from Northern California Kaiser Permanente showed hysterectomy was performed in 21% (774 patients) while uterine-sparing surgery was performed in another 3.9% (n = 143).
-
The Women's Health Initiative reported the effects on overall mortality in their randomized trial of calcium and vitamin D supplementation.
